July 24 (Reuters) - Hikma Pharmaceuticals Plc
* Agreed with Ben Venue Laboratories, Inc. , part of Boehringer Ingelheim Group of companies, to acquire their generic injectables manufacturing site in Bedford, Ohio
* No incremental consideration is payable in relation to Hikma acquiring Ben Venue manufacturing site.
* All manufacturing at Ben Venue site was ceased in December
* Acquisition of assets expected to be slightly dilutive to adjusted EPS in 2014, 2015 and strongly accretive to adjusted EPS from 2016 Source text for Eikon: Further company coverage: